Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron Hj Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J Swen
{"title":"UGT1A1基因型引导的伊立替康给药:优先考虑患者安全的时间","authors":"Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron Hj Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J Swen","doi":"10.2217/pgs-2023-0096","DOIUrl":null,"url":null,"abstract":"<p><p>Tweetable abstract Pretreatment <i>UGT1A1</i> genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of <i>UGT1A1</i> genotype-guided irinotecan dosing in routine oncology care.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"24 8","pages":"435-439"},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<i>UGT1A1</i> genotype-guided dosing of irinotecan: time to prioritize patient safety.\",\"authors\":\"Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron Hj Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J Swen\",\"doi\":\"10.2217/pgs-2023-0096\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tweetable abstract Pretreatment <i>UGT1A1</i> genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of <i>UGT1A1</i> genotype-guided irinotecan dosing in routine oncology care.</p>\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":\"24 8\",\"pages\":\"435-439\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0096\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0096","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.
期刊介绍：
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
